Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus

BACKGROUND: Dapagliflozin (DAPA), a sodium-glucose transporter 2 inhibitor (SGLT2i), attenuates kidney outcomes in patients with not only diabetes mellitus (DM) but also chronic kidney disease (CKD). SGLT2i-derived initial dip in estimated glomerular filtration rate (eGFR) has been considered to red...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Ryo, Taguchi, Kensei, Kaida, Yusuke, Fukami, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813108/
https://www.ncbi.nlm.nih.gov/pubmed/36114995
http://dx.doi.org/10.1007/s10157-022-02277-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813108/
https://www.ncbi.nlm.nih.gov/pubmed/36114995
http://dx.doi.org/10.1007/s10157-022-02277-y

Ejemplares similares